Overall, although future studies are important to validate these results in other mouse models of mitochondrial stress, our data highlight the role of mitochondrial stress-driven endocrine crosstalk via GFRAL signaling, which may potentially enable to develop tailored disease-modifying therapeutics targeting energy balance as well as psychiatric symptoms in patients with mitochondrial disease. The gene discussed is GFRAL; the disease is inborn mitochondrial metabolism disorder.